Objectives: The aim of this study was to determine the probable antibacterial, antitubercular, and antiviral activities of some N 2 -arylidene-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl) acetic acid hydrazides (3a-j). Further structural optimization of the identified lead structures can lead us to new more active potential antibacterial, antitubercular, and antiviral agents.
INTRODUCTION
Infectious diseases caused by bacteria have increased dramatically in recent years. Despite many significant advances in antibacterial therapy, the widespread use and misuse of antibiotics have led to the emergence of bacterial resistance to antibiotics, which is a serious threat to public health. On the other hand, tuberculosis (TB), still remains the leading cause of worldwide death among infectious diseases. 1, 2 In 2014, there were an estimated 9.6 million new TB cases: 5.4 million among men, 3.2 million among women and 1.0 million among children. 3 Additionally, viral infections caused by the rapid emergence of antiviral drug resistant strains have become a serious threat globally. 4 Many diseases are actually caused by the different members of DNA-and RNA-containing viruses. Among DNAcontaining viruses, the herpes group of viruses, particularly herpes simplex virus-1 (HSV-1) primarily causes encephalitis, stomatitis, ocular infections and HSV-2 primarily causes genital lesions, skin eruptions or cytomegalovirus is related with severe morbidity and mortality in patients at risk for disease because of immune system disabilities and varicella-zoster virus is the ethiological agent of chickenpox and shingles. 5, 6 Influenza (INF) viruses, parainfluenza-3 virus, alphaviruses (e.g. sindbis virus), respiratory syncytial virus (RSV) and vesicular stomatitis virus (VSV) are examples of enveloped single-stranded RNAcontaining viruses. VSV causes an economically important disease in horses and cattle. 7 Both RSV and parainfluenza-3 virus are an important cause of respiratory tract infections. 8, 9 Among the heterocyclic rings containing bridgehead nitrogen atom, imidazo [2,1-b] activities.
In continuation of our previous studies on the biological properties of imidazo [2,1-b] thiazole derivatives, [21] [22] [23] [24] [25] [26] [27] in this study, we reported the antibacterial, antitubercular and antiviral activity evaluation of some arylidenehydrazide derivatives bearing imidazo [2,1-b] thiazole moiety. 
MATERIALS AND METHODS

Chemistry
General synthesis of N
2
-arylidene- (6-(4-chlorophenyl) imidazo [2,1-b] thiazol-3-yl)acetic acid hydrazides (3a-3j) 28 A solution of 0.005 mol compound 2 and 0.005 moL of an appropriate aromatic aldehyde in 100 mL ethanol was heated under reflux for 5 h. The precipitate obtained was purified either by recrystallization from ethanol or by washing with hot ethanol.
Biological activity
Antibacterial activity
Minimum inhibitory concentrations (MICs) were determined by the microbroth dilution method using the National Committee for Clinical Laboratory Standards recommendations. 29 MuellerHinton broth (Oxoid, Hemakim, Turkey) was used as the test medium. 
Antitubercular activity
In vitro evaluation of antitubercular activity
Primary screening was conducted at 6.25 mg/mL against Mycobacterium tuberculosis H 37 Rv in BACTEC 12B medium using a broth microdilution assay the Microplate Alamar Blue Assay (MABA). 30 Compounds exhibiting fluorescence were tested in the BACTEC 460 radiometric system. 31 Compounds effecting <90% inhibition in the primary screen were not generally evaluated further. Compounds demonstrating at least 90% inhibition in the primary screen were re-tested at lower concentrations against M. tuberculosis H 37 Rv in order to determine the actual MIC using MABA. The MIC was defined as the lowest concentration effecting a reduction in fluorescence of 90% relative to the controls. Concurrently with the determination of MICs, compounds were tested for cytotoxicity (IC 50 ) in VERO cells at concentrations £6.25 mg/mL or 10 times the MIC for M. tuberculosis H 37 Rv (solubility in media permitting). After 72 h exposure, viability was assessed on the basis of cellular conversion of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide into a formazan product using the Promega CellTiter 96 Non-radioactive Cell Proliferation Assay. Compounds for which the selectivity index (IC 50 : MIC ratio) SI>10 were assumed to possess in vitro activity confirmed in the BACTEC 460 at 6.25 mg/mL.
Microplate alamar blue susceptibility assay
Antimicrobial susceptibility testing was performed in black, clear-bottomed, 96-well microplates (black view plates; Packard Instrument, Meriden, Connecticut, USA) in order to minimize background fluorescence. Outer perimeter wells were filled with sterile water to prevent dehydration in experimental wells. Initial drug dilutions were prepared in either dimethyl sulfoxide or distilled deionized water, and subsequent twofold dilutions were performed in 0.1 mL of 7H9GC (no Tween 80) in the microplates. BACTEC 12B-passaged inocula were initially diluted 1:2 in 7H9GC, and 0.1 mL was added to wells. Subsequent determination of bacterial titers yield 1x10 6 CFU/ mL in plate wells for H 37 Rv. Frozen inocula were initially diluted 1:20 in BACTEC 12B medium followed by a 1:50 dilution in 7H9GC. Addition of 1/10 mL to wells resulted in a final bacterial titers of 2.0x10 5 CFU/mL for H 37 Rv. Wells containing drug only were used to detect autofluorescence of compounds. Addition control wells consisted of bacteria only (B) and medium only (M). Plates were incubated at 37°C. Starting at day 4 of incubation, 20 mL of 10x Alamar Blue solution (Alamar Biosciences/Accumed, Westlake, Ohio, USA) and 12.5 mL of 20% Tween 80 were added to one B well an done M well, and plates were reincubated 37°C. Wells were observed at 12 and 24 h for a color change from blue to pink and for a reading of ≥50.000 fluorescence units (FU). Fluorescence was measured in a Cytofluor II microplate fluorometer (Perseptive Biosystems, Framingham, Massachusetts, USA) in bottom-reading mode with excitation at 530 nm and emission at 590 nm. If the B wells became pink by 24 h, reagent was added to the entire plate. If the well remained blue or £50.000 FU was measured, additional M and B wells were tested daily until a color change occurred, at which time reagents were added to all remaining wells. Plates were then incubated at 37°C, and results were recorded at 24 h post-reagent addition. Visual MICs were defined as the lowest concentration of drug that had prevented a color change. For fluorometric MICs, a background subtraction was performed on all wells with a mean of triplicate M wells. Percent inhibition was defined as 1-(test well FU/mean FU triplicate B wells) x 100. The lowest drug concentration effecting an inhibition of ≥90% was considered the MIC.
BACTEC radiometric method of susceptibility testing
Inocula for susceptibility testing were either from a positive BACTEC isolation vial with a growth index (GI) of 500 or more, or a suspension of organisms isolated earlier on a conventional medium. The culture was well mixed with a syringe and 0.1 mL of a positive BACTEC culture was added to each of the vials containing the test compounds (6.25 mg/mL). The standard vials contained rifampicin (0.25 mg/mL). A control vial was inoculated with a 1:100 dilution of the culture. Each vial was tested immediately on a BACTEC instrument to provide CO 2 in the headspace. The vials were incubated at 37°C and tested daily with a BACTEC instrument. When the GI in the control read at least 30, the increase in GI (DGI) from the previous day in the control was compared with that in the drug vial. The following formula was used to interpret the results:
If a clear susceptibility pattern (the difference of DGI of control and the drug bottle) was not seen at the time the control GI was 30 the vials were read for 1 or 2 additional days to establish a definite pattern of DGI differences.
Antiviral activity
The compounds (3a-j) were evaluated for activity against diverse RNA-and DNA-viruses, using the following cell-based assays To perform the antiviral assays, the virus was added to subconfluent cell cultures in 96-well plates, and at the same time, the test compounds were added at serial dilutions. Appropriate reference compounds were included, i.e. the virus entry inhibitor dextran sulfate 5000, the broad antiviral agent ribavirin, the antiherpetic drug ganciclovir, and the HIV inhibitor azidothymidine. After 3-6 days incubation at 37°C (or 35°C in the case of INF virus), the cultures were examined by microscopy to score the compounds' inhibitory effect on virus-induced cytopathic effect or their cytotoxicity. For some viruses, antiviral and cytotoxic activities were confirmed by the colorimetric 3-(4,5-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium cell viability assay.
RESULTS AND DISCUSSION
The key intermediate 2 was prepared from ethyl (6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)acetate hydrobromide (1) and hydrazine hydrate following the literature method. 33 The synthetic route of the compounds is outlined in Scheme 1. Condensation of 2 with appropriate aromatic aldehyde afforded the corresponding N 2 -arylidene-(6-(4-chlorophenyl)imidazo[2,1-b]thiazol-3-yl)acetic acid hydrazides (3a-j).
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Compounds 3a-j were evaluated for in vitro antibacterial activity against Staphylococcus aureus ATCC 29213, Pseudomonas aeruginosa ATCC 27853 and Escherichia coli ATCC 25922 using the microbroth dilution method 29 .
As can be seen in Table 1 , 3i (2,4-dichlorobenzylidene derivative) showed the highest activity against S. aureus ATCC 29213 and E. coli ATCC 25922 (MIC: 2 μg/mL, 64 μg/mL, respectively).
Compounds 3a-j were evaluated against M. tuberculosis H 37 Rv (ATCC 27294) in BACTEC 12B medium using a broth microdilution assay, the MABA. The primary antituberculosis screening was performed in accordance with the protocol of the Tuberculosis Antimicrobial Acquisition and Coordinating Facility Southern Research Institute 30 . Rifampin was used as the control drug in the tests. Compounds demonstrating a percent inhibition of bacterial growth of greater than or equal to 90% in the primary screen were retested against M. tuberculosis H 37 Rv, to determine the actual MIC in the MABA. The MIC was defined as the lowest concentration effecting a reduction in fluorescence of 90%, relative to controls. This value was determined from the doseresponse curve as the IC 90 using a curve fitting program. Any IC 90 value of ≤10 μg/mL was considered "Active" for antitubercular activity. Compounds active in the initial screen were tested for IC 50 in Vero cells. Cytotoxicity was determined from the dose-response curve as the IC 50 using a curve fitting program. Concurrent with the determination of MICs, compounds were tested for cytotoxicity in Vero cells at concentrations 10x the MIC for M. tuberculosis H 37 Rv. Most of the tested compounds showed weakly antitubercular activity and cytotoxicities of the compounds were found to be very high ( Table 2 ).
The compounds (3a-j) were also evaluated against INF A/ H1N1 subtype (A/Ned/378/05), INF A/H3N2 subtype (A/ HK/7/87), INF B (B/Ned/537/05) in MDCK, FCoV, FHV in CRFK, parainfluenza-3 virus, reovirus-1, sindbis virus, coxsackie B4 virus, punta toro virus in Vero, HSV-1 (KOS), HSV-2 (G), HSV-1 TK KOS ACV, vaccinia virus, VSV, in HEL and VSV, coxsackie B4 virus and RSV in HeLa cell cultures. As can be seen in Table 3 , the most active compound was R=2,4-dichlorophenyl substituted 3i. It inhibited FCoV with EC 50 of 7.5 μM. R=4-hydroxyphenyl substituted derivative 3c, inhibited HSV-1 (KOS), HSV-2 (G), HSV-1 TK KOS ACV, vaccinia virüs and VSV with EC 50 of 9, 27, 32, 16 and 32 μM, respectively. R=3-methoxy-4-hydroxyphenyl substituted 3g showed EC 50 values of 20 and 14 μM for HSV-1 (KOS) and v virus, respectively (Table 4) 3a >100 >100 >100 >100 >100 >100 3b >100 >100 >100 >100 >100 >100 3c ≥100 9 27 32 16 32 3d 100 >20 >20 >20 >20 >20 3e >100 >100 >100 >100 >100 >100 3f >100 >100 >100 >100 >100 >100 3g 500 20 >100 >100 14 >100 3h 100 >20 >20 >20 >20 >20 3i 100 >20 >20 >20 >20 >20 3j >100 >100 >100 >100 >100 >100 Required to reduce virus-induced cytopathogenicity by 50%
